A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Alzheimer's Disease
In brief
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Key facts
- Study ID
- NCT07094516
- Run by
- Novartis Pharmaceuticals
- People needed
- 407
- Starts
- 2025-08-07
- Expected to finish
- 2030-12-31
- Last updated by the study team
- 2026-06-26
Who can join
Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Irvine Center for Clinical Research — Irvine, California, United States (enrolling)
- University of California San Diego — La Jolla, California, United States (enrolling)
- University of California at Los Angeles — Los Angeles, California, United States (enrolling)
- Jem Research Institute — Atlantis, Florida, United States (enrolling)
- Visionary Investigators Network — Aventura, Florida, United States (enrolling)
- K2 Medical Research LLC — Maitland, Florida, United States (enrolling)
- K2 Medical Research LLC — Maitland, Florida, United States (enrolling)
- Renstar Medical Research — Ocala, Florida, United States (enrolling)
- Charter Research The Villages — The Villages, Florida, United States (enrolling)
- Alzheimers Research Treatment Ctr — Wellington, Florida, United States (enrolling)
- Alzheimers Research Treatment Ctr — Wellington, Florida, United States (enrolling)
- Conquest Research — Winter Park, Florida, United States (enrolling)
- Hawaii Pacific Neuroscience LLC — Honolulu, Hawaii, United States (enrolling)
- University of Kansas Hospital — Fairway, Kansas, United States (enrolling)
- ActivMed Practices and Research — Methuen, Massachusetts, United States (enrolling)
- Citizens Memorial Hospital Neurology CLinic — Bolivar, Missouri, United States (enrolling)
- Lou Ruvo Center for Brain Health — Las Vegas, Nevada, United States (enrolling)
- UNC Hosp Invest Drug Serv Pharm — Chapel Hill, North Carolina, United States (enrolling)
- The Ohio State University — Columbus, Ohio, United States (enrolling)
- Neural Net Research — Portland, Oregon, United States (enrolling)
- Abington Neurological Associates Ltd — Willow Grove, Pennsylvania, United States (enrolling)
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States (enrolling)
- University of Washington Medical Center — Seattle, Washington, United States (enrolling)
- Novartis Investigative Site — Camperdown, New South Wales, Australia (enrolling)
- Banner Alzheimers Institute — Phoenix, Arizona, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.